null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

Net debt ~$750M+; Total debt-to-EBITDA ~6-8x; a 20% EBITDA decline would push leverage to ~8-10x, stressing covenant thresholds significantly.

Predominantly fixed-rate high-yield debt (~10% coupon); a 20% revenue decline reduces EBITDA ~$50-70M, compressing interest coverage ratio from ~1.5x to near 1.0x.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) U.S. state-by-state regulatory borders restrict interstate cannabis flow. 2) Cultivation inputs (fertilizers, lighting) exposed to China-sourced component disruptions.

Cresco operates exclusively in U.S. domestic cannabis; no material international revenue exposure; sovereign currency devaluation risk is effectively zero.

Operations in ~10 U.S. states only; zero international revenue; no sovereign currency devaluation exposure; entirely USD-denominated revenue base.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of inputs; cultivation inputs diversified across multiple suppliers, though state-licensed dispensary real estate creates localized dependency.

Vertically integrated cannabis operator; minimal cloud infrastructure dependency; cloud disruption would affect POS/ERP systems but not core cultivation or retail operations.

Retail cannabis dispensary network supplemented by wholesale CPG brand distribution; cloud termination primarily disrupts inventory management and e-commerce ordering.

Moderate API coupling via seed-to-sale compliance platforms (Metrc); Metrc is state-mandated, creating non-substitutable regulatory reporting lock-in.

Primary revenue from cannabis product sales; not an investment contract; Howey Test risk is negligible—business model is product retail, not a securities offering.

Very High

Minimal GDPR exposure given U.S.-only operations; CCPA exposure moderate for California dispensary customer data; loyalty program data collection increases compliance obligation.

Moderate; as one of largest MSOs, wholesale market share in Illinois/Pennsylvania could attract scrutiny; 280E tax burden currently limits acquisition-driven consolidation.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Nearly 100% transactional; cannabis retail and wholesale are point-of-sale purchases with no meaningful recurring subscription or multi-year contract revenue streams.

Retail dispensary sales (~60%) and wholesale branded product distribution (~40%); both are transactional CPG-style revenue with no subscription component.

State-regulated pricing with limited flexibility; wholesale commodity pricing pressure from oversupply (IL, PA, OH) compresses margins; retail pricing power moderate via brand premium.

Low-to-moderate; cannabis commoditization and interstate trade barriers suppress pricing power; branded products (Cresco, Mindy's) provide marginal premium but limited elasticity.

Gross margin ~45-50% reported; cannabis-specific 280E tax treatment effectively reduces economic gross margin to ~30-35% on a fully-taxed comparable basis.

Minimal free-rider risk; cannabis requires age-verified purchase; dispensary loyalty programs retain customers but competition within legalized states drives switching behavior.

Revenue growth is largely headcount-linear; each new dispensary or cultivation facility requires proportional labor; limited software-style operating leverage in retail model.

High marginal cost; expansion requires licensed facilities, cultivation buildout, and retail staff; doubling revenue likely requires ~80-90% proportional headcount increase.

Not a franchise model; company-owned and operated dispensaries; compliance risk is regulatory (state cannabis law) rather than franchise network drift.

At 10x scale, CAC would rise significantly due to dispensary saturation and marketing restrictions; digital advertising bans on cannabis limit scalable CAC-efficient channels.

No meaningful network effects; cannabis retail is geographically constrained, single-player transactions with no user-to-user value creation or platform dynamics.

AI displacement risk is low for cultivation and retail; modest AI upside in inventory optimization and demand forecasting; core operations remain labor and asset intensive.

Moderate recession resistance; cannabis shows trading-down behavior (flower over concentrates); medical cannabis is defensive, adult-use discretionary spending is more cyclical.

Adult-use recreational cannabis consumers (~60-65% of revenue); highly fragmented, no single customer represents material concentration risk.

Medical cannabis patients (~25-30% of revenue); stickier segment with physician-driven demand, but declining as adult-use markets expand in overlap states.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

CapEx shifting from greenfield cultivation buildout to dispensary optimization and efficiency; legacy over-built cultivation facilities represent stranded capital risk in oversupplied markets.

0001832928

CRLBF